Please login to the form below

Not currently logged in
Email:
Password:

Nuvigil

This page shows the latest Nuvigil news and features for those working in and with pharma, biotech and healthcare.

Teva halts development of Nuvigil in bipolar disorder

Teva halts development of Nuvigil in bipolar disorder

Nuvigil made $347m for Teva during 2012 in these indications, but the company was keen to expand its use ahead of patent expiry in 2016. ... Any further plans to expand the use of the product now seem unlikely, with Dr Hayden commenting: “We will

Latest news

  • Teva suffers setback as Nuvigil fails late-stage trial Teva suffers setback as Nuvigil fails late-stage trial

    Disappointing results in treating bipolar disorder but drug development continues. Teva's Nuvigil has failed to show efficacy in a phase III trial in bipolar disorder, although the pharma company insists ... Some analysts believe the availability of

  • Cephalon jet lag application rejected

    Cephalon has dropped its bid to get sleep disorder drug Nuvigil approved as a treatment for jet lag after a second rejection from the US FDA. ... Cephalon stressed that Nuvigil met the primary endpoints of pivotal studies comparing the drug to placebo.

  • Cephalon posts record sales

    The quarter also saw Cephalon launch Nuvigil tablets and file a supplemental new drug application with the US Food and Drug Administration (FDA) for the drug as a treatment for excessive ... If Nuvigil is approved it will be the first acute indication

  • State of mind

    Acute mania. MEM 1003. Bayer. Acute mania. Armodafinil. Nuvigil; Cephalon. Bipolar disorder. ... Armodafinil (Nuvigil, Cephalon) is currently being investigated as a therapy for bipolar disorders.

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics